
MS Virtual 2020

Read the full Report (pdf)
8th Joint ACTRIMS and ECTRIMS Meeting 11-13 September 2020
CONTENTS
Online First
COVID-19 and MS

Age and EDSS are risk factors for severe COVID-19
Biomarkers

Serum NfL as biomarker for suboptimal treatment response
Grey matter network measures predict disability and cognition
Treatment Strategies and Results
Management of progressive MS with approved DMT
Outcomes in patients on alemtuzumab with thyroid adverse events
Safety and efficacy of dimethyl fumarate: 13 years of follow-up
No new safety signals in ofatumumab open-label data

TERIKIDS trial extension of teriflunomide in paediatric MS
Teriflunomide improves satisfaction versus prior DMT regardless of age
Safety and efficacy of cladribine, glatiramer acetate, and more
Novel Treatment Directions
